These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1969293)

  • 21. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ; Sitko GR; Mellott MJ; Nutt EM; Lehman ED; Friedman PA; Dunwiddie CT; Vlasuk GP
    Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA; Lee P; Rios G; Kottke-Marchant K; Topol EJ
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs.
    Yao SK; Ober JC; Garfinkel LI; Hagay Y; Ezov N; Ferguson JJ; Anderson HV; Panet A; Gorecki M; Buja LM
    Circulation; 1994 Jun; 89(6):2822-8. PubMed ID: 8205697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endogenous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis.
    Yao SK; Akhtar S; Scott-Burden T; Ober JC; Golino P; Buja LM; Casscells W; Willerson JT
    Circulation; 1995 Aug; 92(4):1005-10. PubMed ID: 7641335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Serebruany V; Herzog WR
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis.
    Martin U; Sponer G; Strein K
    Int J Hematol; 1992 Oct; 56(2):143-53. PubMed ID: 1421176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS; Bentley RG; Morgan SR; Kasiewski CJ; Chu V; Perrone MH; Leadley RJ
    Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog.
    Kopia GA; Kopaciewicz LJ; Fong KL; Crysler CS; Boyle K; Ruffolo RR
    J Cardiovasc Pharmacol; 1988 Sep; 12(3):308-16. PubMed ID: 2464103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis.
    Martin U; Sponer G; König R; Smolarz A; Meyer-Sabellek W; Strein K
    Blood Coagul Fibrinolysis; 1992 Apr; 3(2):139-47. PubMed ID: 1606285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
    Saitoh S; Saito T; Otake A; Owada T; Mitsugi M; Hashimoto H; Maruyama Y
    Arterioscler Thromb; 1993 Apr; 13(4):563-70. PubMed ID: 8385480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
    Martin U; Dörge L; Fischer S
    Br J Pharmacol; 1996 May; 118(2):271-6. PubMed ID: 8735626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
    Fitzgerald DJ; Fitzgerald GA
    Proc Natl Acad Sci U S A; 1989 Oct; 86(19):7585-9. PubMed ID: 2508092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ; Follenfant MJ; Ford AJ
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis.
    Mellott MJ; Holahan MA; Lynch JJ; Vlasuk GP; Dunwiddie CT
    Circ Res; 1992 Jun; 70(6):1152-60. PubMed ID: 1576736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T; Gold HK; Leinbach RC; Yaoita H; Fallon JT; Guerrero L; Napier MA; Bunting S; Collen D
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic efficacy of single subcutaneous administration of a recombinant nematode anticoagulant peptide (rNAP5) in a canine model of coronary artery thrombolysis.
    Rebello SS; Blank HS; Lucchesi BR
    Thromb Res; 2000 Jun; 98(6):531-40. PubMed ID: 10899352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced thrombolysis by a factor XIIIa inhibitor in a rabbit model of femoral artery thrombosis.
    Leidy EM; Stern AM; Friedman PA; Bush LR
    Thromb Res; 1990 Jul; 59(1):15-26. PubMed ID: 1975957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T; Gold HK; Yaoita H; Leinbach RC; Guerrero JL; Jang IK; Holt R; Fallon JT; Collen D
    J Am Coll Cardiol; 1990 Sep; 16(3):714-22. PubMed ID: 2117620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.